PRDM16 was originally identified through the aberrant expression of its short variant in acute myeloid leukemia.[8] However, the majority of recent studies linking PRDM16 to disease is in the context of adipose tissue metabolism, including browning and thermogenesis of adipocytes and the beigeing of adipocytes.[15, 27, 28] Closely relevant to our present work, two studies showed that PRDM16 was anti‐fibrotic in adipose tissues.[14, 15] Cibi et al. Here, PRDM16 is linked to acute myeloid leukemia.